Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
32.43
-0.27 (-0.83%)
At close: Jul 6, 2026, 4:00 PM EDT
33.00
+0.57 (1.76%)
After-hours: Jul 6, 2026, 7:19 PM EDT
Stoke Therapeutics Employees
Stoke Therapeutics had 170 employees as of December 31, 2025. The number of employees increased by 42 or 32.81% compared to the previous year.
Employees
170
Change (1Y)
42
Growth (1Y)
32.81%
Revenue / Employee
$188,706
Profits / Employee
-$998,629
Market Cap
2.02B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 170 | 42 | 32.81% |
| Dec 31, 2024 | 128 | 18 | 16.36% |
| Dec 31, 2023 | 110 | -7 | -5.98% |
| Dec 31, 2022 | 117 | 15 | 14.71% |
| Dec 31, 2021 | 102 | 23 | 29.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| ADMA Biologics | 647 |
| Recursion Pharmaceuticals | 600 |
| Lakefront Biotherapeutics NV | 558 |
| Nuvation Bio | 307 |
| Monte Rosa Therapeutics | 187 |
| Precigen | 160 |
| Aurinia Pharmaceuticals | 128 |
STOK News
- 6 days ago - Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR study - TheFly
- 6 days ago - Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome - Business Wire
- 20 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 4 weeks ago - Stoke Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Stoke Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Stoke Therapeutics Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Stoke Therapeutics to Present at Upcoming Investor Conferences in June - Business Wire
- 2 months ago - Stoke Therapeutics reports Q1 EPS (79c), consensus (84c) - TheFly